Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Piper Sandler 34^th Annual Healthcare Conference being held on November 29 – December 1, 2022, in New York, NY.   

Presentation Details:

Event: Piper Sandler 34^th Annual Healthcare Conference
Presentation Date: Tuesday, November 29, 2022
Presentation Time: 9:10am ET
Location: Lotte New York Palace   

A live webcast of the presentation will be accessible on the Company’s website in the Investors section under News & Events at www.inhibikase.com.

About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Lexington, Massachusetts.

Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Contacts:

Company Contact:
Milton H. Werner, Ph.D.
President & CEO
678-392-3419
info@inhibikase.com

Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com

Related Post
VERU LAWSUIT ALERT: Levi & Korsinsky Notifies Veru Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Bluerock Total Income+ Real Estate Fund Celebrates 10-Year Anniversary, With Highest Risk-Adjusted Returns Among All 1940 Act Funds Over 1/3/5 and Since Inception Periods
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Kiromic BioPharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2022
EZGO Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirements
Levi & Korsinsky Notifies Argo Group International Holdings, Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline